Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rocket Lab USA Inc (RKLB) vs Tilray Brands Inc (TLRY) Price & Performance

Rocket Lab USA IncTrade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

Rocket Lab USA Inc vs Tilray Brands Inc — how do they compare? Rocket Lab USA Inc trades at $68.25 (market cap $43.74B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Rocket Lab USA Inc is far larger — about 82.4× Tilray Brands Inc's market cap, and Rocket Lab USA Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rocket Lab USA Inc for 29 Days and Tilray Brands Inc for 31 Days on average.

RKLBTLRY
Market Cap
$43.74B$530.54M
Volume
22,892,5819,099,075
Sector
IndustrialsHealth
52-Week High
$150.23$21.00
52-Week Low
$39.48$3.57
Typical Hold Time
29 Days31 Days
Enterprise Value
$41.57B$684.46M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rocket Lab USA Inc

Rocket Lab (RKLB) trades at $68.21, down 5.16% today, amid a bearish technical signal despite recent positive business developments. The company secured its largest-ever commercial Electron deal with Synspective for 20 launches, boosting its backlog past 100 missions. However, financials show negative profitability with a net income margin of -21.51% and elevated valuation ratios including P/S of 51.96. Technical indicators show bearish momentum with key support at $64.

The outlook remains mixed with strong analyst bullishness (76% buy ratings, $107 consensus target) contrasting with fundamental challenges. Investment opportunity lies in execution of the growing launch backlog and Neutron rocket development, while risks include sustained losses, SpaceX competition, and high valuation multiples requiring significant future growth to justify.

Tilray Brands Inc

Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.

The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RKLB
92% Buy8% Sell
Avg holding period · 29 Days
TLRY
54% Buy46% Sell
Avg holding period · 31 Days

Top news

Latest headlines on both assets

About Rocket Lab USA Inc

Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.

Read more on RKLB →

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY →